 |
Purdue's Licensing and Business Development executives: from left, Allen Downs, Ann Kraft, and Jim Dolan |
The Benefits of Partnering with Purdue Pharma L.P.
In today's competitive marketplace, alliances allow companies to combine resources and expertise to advance research and bring innovative products to market. By building strong alliances with high-quality, research-driven organizations, we provide new and improved treatments for diseases and their symptoms, and deliver the best possible care for patients.
Fully Integrated Pharmaceutical Operations
Purdue provides partner companies with extensive expertise in discovery, clinical development, project management, regulatory affairs, manufacturing, marketing, and sales. A dedicated Alliance Management function ensures that every dimension and detail involved in our collaborations gets the attention required. Purdue has regulatory expertise and experience in gaining approval from the U.S. Food and Drug Administration (FDA). Our national U.S. sales and marketing organization has the critical mass and know-how to commercialize new products quickly and effectively.
Global Reach
Purdue Pharma and its independent associated companies (including the Mundipharma/Napp companies) have a presence in more than 30 countries and a staff of more than 5,000. Each of these international companies is a leader within their respective market for key therapeutic areas.
Expertise in Pain Management
Purdue has long-standing expertise in pain management and has transformed clinical practice to better serve the needs of patients with pain. We have conducted extensive research into the development of analgesics that provide safe and effective pain relief to patients. We work extensively with physicians, opinion leaders, and patient advocacy groups to ensure that pain is appropriately recognized and treated.
Purdue and Shionogi & Co., Ltd., one of Japan's largest research-based pharmaceutical companies, are collaborating on the discovery and development of novel, non-opioid medications to treat pain. The research, which targets cellular receptors known to modulate pain responses, is being conducted jointly at Purdue's research center in Cranbury, New Jersey, and Shionogi's laboratories in Osaka, Japan.
Purdue has an exclusive U.S. licensing and co-promotion agreement with Labopharm Inc. of Laval, Canada for Ryzolt® (tramadol HCl extended-release tablets), an extended release formulation of tramadol.
Expanding into Related Therapeutic Areas
Purdue has an exclusive license and collaboration agreement with Transcept Pharmaceuticals, Inc. to commercialize Intermezzo® (zolpidem tartrate sublingual tablet), a product for insomnia currently under FDA review.
Additionally, Purdue Pharma L.P. and its associated company, Mundipharma International Corporation Limited, entered into a global strategic alliance with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity's discoveries and early clinical programs in oncology (outside the United States) and neuropathic pain (worldwide).
Purdue's Therapeutic Areas of Interest
Purdue's licensing strategy seeks to identify late-stage products within the following therapeutic areas:
- Pain management - both non-opioids and opioids
- Sleep disorders
- Gastrointestinal disorders